Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

In the final weeks of his administration, President Biden’s Food and Drug Administration quietly ended the “shortage” of tirzepatide, a popular GLP-1 medication. That means on March 19 ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful weight-loss drug, Zepbound. Tirzepatide will cost less than $ ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.

The FDA says state-licensed compounding pharmacies must immediately stop making most compound versions of GLP-1 drugs based on tirzepatide. Larger outsourcing pharmacies making compound versions ...

12-week chronic study GLP-1-H24-4, in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of ...

GLP-1 receptor agonists work by: Popular GLP-1 medications include Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro). These drugs have been proven to facilitate substantial weight loss when ...

As a reminder, the 5 Study arms are as follows: "The ability to study two GLP-1 drugs - semaglutide and tirzepatide - in a single study that together comprise well over 90% of the global GLP-1 ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads ... glucagon-like peptide 1 (GLP-1) receptor agonists ...